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Aim. To find putative diagnostic and prognostic markers of cancerogenesis. Methods. Analysis of microarray
and SAGE data, quantitative PCR (Q-PCR), bisulfite sequencing, methylation-specific PCR. Results. Bioinfor-
matic analysis of microarray and SAGE database revealed that genes, encoding the glutathione peroxidase 1
and 3 (GPX1 and GPX3) were expressed at low levels in renal cancers. The relative gene expression of GPX1
and GPX3 that was widely inactivated in clear-cell renal cell carcinoma (ccRCC) was confirmed by Q-PCR. No
correlation between expression levels and promoter methylation was found. It was found, however, that an allele
with five ALA repeats in the N-terminal region of GPX1 is the most frequent polymorphic variant in ccRCC
patients. Conclusions. Our data support the hypothesis that GPX1 and GPX3 are involved in tumorigenesis of
ccRCC and could be putative TSGs (tumor suppressor genes) in renal cancer.
Keywords: renal cell carcinoma, genetic and epigenetic regulation, chromosome 3, quantitative real time PCR,
methylation status.
Introduction. Renal cancer is among the ten most com-
mon causes of cancer-related death in adults [1]. The
common subtypes of renal tumors are clear-cell renal
cell carcinoma (ccRCC) (83.2 %), papillary (11.3 %)
and chromophobe carcinoma (4.3 %) [2]. The ccRCC is
characterized by a variable and unpredictable clinical
course. Patients with this disease have a poor 5-year sur-
vival [3]. Thus, accurate prediction of the course of di-
sease is important for treatment. In spite of the large
number of studies, the molecular mechanisms associa-
ted with tumor growth, metastasis, and progression of
ccRCC are not sufficiently explored. One of the most
important tasks is the identification of tumor suppres-
sor genes (TSGs) [4].
One of the approaches to find a putative TSG is to
analyze an open bioinformatic databases, for example,
oligonucleotide microarrays (microchips) database and
serial analysis of gene expression (SAGE). DNA-mic-
roarray technology, based on cDNA or oligonucleotide,
allows obtaining quantitative information about the ex-
pression profiles in the studied samples. On the other
hand, though the microarray technology allows an ana-
lysis of expression level of thousands genes, these genes
usually have been already identified. SAGE is a tech-
nology for quantitative characterization of transcriptom,
i. e. the totality of mRNA in a particular type of cell or
tissue [5, 6].
We have used different approach to perform a lar-
ge-scale search for changes of gene expression in renal
cancer. This may lead to identification of the genes that
could be involved in renal carcinogenesis and could ser-
ve as diagnostic and prognostic tumor markers. After
the search in SAGE and Microarray databases, we con-
firmed our findings by Q-PCR. We have also investiga-
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ted genetic and/or epigenetic changes of candidate ge-
nes in the experimental system.
Using the proposed approach, we analyzed 83 tu-
mor samples in comparison to 84 normal tissues in 11
independent experiments.
Materials and methods. Analysis of microarray
and SAGE databases. To analyze the databases «R
Project» for Statistical Computing (www.r-project.org)
was used. To process the initial microarray data availab-
le publicly the Bioconductor package was used. An addi-
tional normalization of processed data was done, using
a method suited for Q-PCR. Differentially expressed
genes were analyzed by limma package. The Limma gi-
ves a possibility to analyze many RNA targets simulta-
neously [7].
The following main steps were performed: reset-
ting bioinformatics analysis in the context of general li-
near models with arbitrary units and contrasts of inte-
rest, deriving consistent, closed form estimators for the
hyper parameters, using the marginal distributions of
the observed statistics, reformulating the posterior odds
statistic in terms of a moderated t-statistic in which po-
sterior residual standard deviations are used in place of
ordinary standard deviations.
SAGE map is a serial analysis of gene expression da-
ta repository supporting public use and dissemination of
SAGE data. All of the SAGE libraries are present on the
following website: ncbi.nlm.nih.gov/projects/SAGE/.
The main idea was to compare all available libraries of
normal kidney tissues with renal cancer libraries, using
SAGE Digital Gene Expression Displayer (DGED) to
find genes with different expression in kidney cancers.
Tissue samples. Surgically removed tumors and sur-
rounding normal tissues were obtained from Kyiv Na-
tional Urological Center (Kyiv, Ukraine). All tumor spe-
cimens were characterized according to the Internatio-
nal System of Clinico-Morphological Classification of
Tumors (TNM), based on the tumor-node-metastasis
and staging classification of 1989 [8] and WHO criteria
classification of 1999 [9]. The gene expression pattern
was analyzed in 12 ccRCC samples and 12 correspon-
ding normal tissues from the same patients: 6 samples
were of stage 1–2 and 6 were of stage 3–4. The mean
age of patients at diagnosis was 57.4 ± 11.6 (in the ran-
ge of 36–69 years). «Normal» matched controls were
obtained at the distance of minimum 2 cm from the tu-
mor site and confirmed histologically as normal renal
epithelial cells. The 13 ccRCC samples were investiga-
ted for methylation status and trinucleotide polymor-
phism (7 samples were of stage 1–2 and 6 samples were
of stage 3–4). Three of these samples were studied,
using bisulfite sequencing.
The present study was performed in accordance with
the permission from the Ethical Committee of IMBG.
Isolation of genomic DNA and total RNA. Genomic
DNA was isolated, using DNA purification Kit («Fer-
mentas», Lithuania), according to the manufacturer’s re-
commendations. Total RNA was isolated from all fresh-
frozen renal tumors and from normal tissues surroun-
ding the tumors by homogenization with RNeasy Mini
Kit («QIAGEN», USA), according to the producer’s
protocol. Quality of genomic DNA and total RNA was
assessed by agarose gel electrophoresis; their concen-
tration was measured, using a spectrophotometer Nano
Drop ND-1000 («NanoDrop Technologies Inc.», USA).
The samples, used for the Q-PCR reactions, were of high
molecular weight and pure from contaminations (an
OD 260/280 ranging from 1.6 to 1.8). From each RNA
sample, 1 g of total RNA was treated with DNAseI
and reversely transcribed in duplicates, as well as nega-
tive controls without enzyme, using the RevertAid
™ H
Minus First Strand cDNA Synthesis Kit («Thermo Sci-
entific», SE, Sweden).
Analysis of gene expression levels. We have used Q-
PCR to study a relative gene expression, using «Bio-
Rad» iQ5 (USA). The reactions were performed, using
SYBR Green. TBP was used as a reference gene [11].
Primers for GPX1 and GPX3 were designed, using the
Primer3 (http://frodo.wi.mit.edu/primer3/) and Oligo6.24
program and were synthesized by «Invitrogen» (BV,
Netherlands). For mRNA detection the following pri-
mers were used:
GPX1for: 5'-CCAAGCTCATCACCTGGTCT-3';
GPX1 rev: 5'-TCGATGTCAATGGTCTGGAA-3';
GPX3 for: 5'-TACGAGTACGGAGCCCTCAC-3';
GPX3 rev: 5'-CCAGAATGACCAGACCGAAT-3';
TBP for: 5'-GAACCACGGCACTGATTTTC -3';
TBP rev: 5'-CACAGCTCCCCACCATATTC-3'.
Primers for mRNA detection were selected to span
for at least one big intron (more than 1 kb). Each Q-PCR
reaction mix contained 12.5 l of 2  YBR Green PCR
Master Mix («Fermentas»), forward and reverse primers
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at optimized concentrations of 400 nM, 10 ng/l cDNA
template and a sterile water to make a final volume of
25 l. The reaction profile was: an initial step at 72 °C
for 2 min, denaturation at 95 °C for 10 min, then 35 cyc-
les of denaturation at 95 °C for 20 s, annealing at 60 °C
for 20 s and extension at 72 °C for 40 s. To generate stan-
dard curves for the selected primers and the reference
primers a log10 dilution series of cDNA was prepared
at concentrations ranging from 1 ng to 100 ng. A GPXs
expression level was estimated by the 2-CP method
of relative quantification [12].
Analysis of methylation status. Methyl-specific PCR
for GPXs fragment amplification was carried out with
primers specific to the methylated and unmethylated
DNA sequences of GPXs CpG island. Blood gDNA
treated with SssI-methyltransefrase («New England
Biolabs», UK) was used as a positive control. The me-
thylation status of genes was determined in three selec-
ted samples by bisulfite sequencing as described earlier
[10]. Bisulfite treatment was performed, using the EZ
DNA Methylation Kit («Zymo Research Corporation»,
USA). PCR was carried out for 35 cycles, comprising
30 s denaturation at 94 °C, 30 s annealing at 56 °C, and
1 min extension at 72 °C. The cycling started by 2 min
denaturation at 94 °C. The PCR products were purified,
using the DNA Clean and Concentrator Kit («Zymo Re-
search Corporation»), according to the manufacturer’s
protocol. PCR products were cloned, using the TOPO
TA Cloning Kit for Sequencing («Invitrogen»). Plasmid
DNA was isolated, using a Zyppy Plasmid Miniprep Kit
(«Zymo Research Corporation»). Sequencing was per-
formed, using the BigDye Terminator Cycle Sequen-
cingReady Reaction kit v1.1 and ABI Prism 3100 Ge-
netic Analyzer («Applied Biosystems», USA). The
following primers were used for bisulfite sequencing of
GPXs («Invitrogen»):
GPX3 BS for: 5'-GGGATTTGATTTTTATTTTT
TTGTTTAGATTTGTT-3';
GPX3 BS rev: 5'- AAAAAAAACCTTCCTCCC
TTAATCATTCTA-3';
GPX1 BS rev: 5'-CAAAAAACCCAAACTCAC
AAACTCC-3';
GPX1 BS for: 5'-AGTTTTTGGAAGGGTAATT
TGGAT-3'.
Loss of heterozygosity. PCR was carried out for 28
cycles, comprising 30 s denaturation at 94 °C, 30 s an-
nealing at 68 oC for GPX1 and 63 oC for GPX3, and 1
min extension at 72 °C. The cycling started by 2 min
denaturation at 94 °C. One of the primers was labeled
by Ñó5 («IBA», USA):
GPX1 for: 5'-Ñó5GAAAACTGCCTCTGCCACGT
G ACC-3';
GPX1 rev: 5'-CGAGAAGGCATACACCGACTGG
GC-3';
GPX3 for: 5'-Ñó5GATGTGAAGCCACTTCGT C-3';
GPX3 rev: 5'-ATG GTG CTG GCC TGT CTA T-3'.
Denaturing PAAG electrophoresis was used to de-
termine the exact size of trinucleotide repeats. The elect-
rophoresis was conducted on automatic laser sequencing
machine «ALF express» («Pharmacia Biotech», USA).
The mixture, containing 3 l of amplification product
and 2 ml of loading buffer (0.01 % bromphenol blue,
0.01 % xylene cyanol, 98 % formamide), was denatu-
red at 95 °C for 5 min before electrophoresis.
Statistical analysis. The nonparametric Wilcoxon
test was used to compare mRNA expression of target
and reference genes for the same sample. Then groups
of samples were compared in respect to the average level
of mRNA decrease (LDav) and the frequency of de-
crease (FD). The LD was calculated as 1/R, where R is
an mRNA copy number ratio (R) of a target gene versus
reference gene and reflects the n-fold factor by which
the mRNA content decreased in the tumor compared to
normal tissue [10]. The nonparametric Kruskal – Wal-
lis and Mann – Whitney rank-sum tests were used to
test mRNA differences (both LDav and FD) for each
target gene, in tumors with and without metastases. The
nonparametric Spearmen’s criterion was used to calcu-
late the coefficient of correlation between the LDav for
each set of pairs of target genes. P-values < 0.05 were
considered statistically significant. All statistical pro-
cedures were performed, using the BioStat software.
Results and discussion. Microarray and SAGE da-
ta analysis. To identify putative markers of ccRCC as
targets for novel therapeutic drugs, we have investiga-
ted genome-wide expression profiles of all human ge-
nes in ccRCCs, using a bioinformatics analysis of cDNA
microarray data. The results of 11 independent cases of
analysis (such as GSE11985, GSE12114, GSE781,
GSE12630 and others) were compared with the data
reported for 84 normal and 83 tumor samples. In order
to find genes with different expression level during kid-
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ney carcinogenesis, we have also compared the kidney
tumor library with 2 libraries of normal tissues, using
the SAGE Digital Gene Expression Displayer (DGED).
Bioinformatic analysis showed that the TBP gene may
be used as a reference gene to investigate the gene ex-
pression pattern in human renal cell carcinomas, verify-
ing the results that were published earlier [11].
The 12 genes, that followed a pattern reported in
Microarray and SAGE databases, were found. 2 genes –
GPX1 and GPX3 were chosen to study genetic and epi-
genetic changes, due to their function in progression
and metastasing of renal tumor. Our data supported the
hypothesis that these 2 genes are involved in tumorige-
nesis of ccRCC, due to the fact, that GPX1 and GPX3
expression was simultaneously decreased in renal cell
carcinomas, according to microarray and SAGE analysis.
Levels of relative gene expression. The GPX1 ex-
pression decreased significantly (from 2 to 94 fold) at
the mRNA level (LD) in 87 % of RCC samples (8 of 12,
P < 0.002) in comparison with surrounding normal tis-
sue (Fig. 1), according to Q-PCR data. While no signi-
ficant association was found between gene expression
level and gender or age, it should be pointed out that
GPX1 expression has a trend to correlate with the his-
tological grade.
TheGPX3 expression was down-regulated in all of
12 ccRCC samples in comparison with surrounding nor-
mal tissue (Fig. 2). Also no significant association was
found between gene expression level and gender or age.
The obtained data on relative expression of GPX1
and GPX3 confirm the results of microarray and SAGE
analysis.
To reveal possible mechanisms of gene expression
decline, the methylation status of gene promoters was
investigated, because it might be an epigenetic inactiva-
tion of these genes. It might be and/or a loss of hetero-
zygosity as well.
Analysis of methylation status. To understand the
mechanisms, underlying the observed down-regulation
of GPXs in renal cancer samples, an analysis of promo-
ter methylation was performed. CpG islands were iden-
tified in the exon1/intron1 region of GPX3. However,
no CpG islands were identified in the promoter region
up to 3,000 bp of GPX3. Methylation-specific PCR for
GPX1 andGPX3was performed for 13 ccRCC samples
and surrounding normal tissues. No methylation was
found in any of renal cancer samples. Bisulfite sequen-
cing was performed on 3 samples (2, 9, and 11) from re-
nal cancer and 3 normal tissues. The results of methyla-
tion-specific PCR confirmed the absence of changes in
methylation profile, indicating that other mechanism of
inhibition of gene expression should be responsible, for
example, genetic changes.
Loss of heterozygosity study. The loss of heterozy-
gosity (LOH) method was used for a search for dele-
tion. However, no LOH was found for the GPX1 and
GPX3 genes.
Trinucleotide repeats determining. The allele’s ana-
lysis was performed to investigate the trinucleotide po-
lymorphic locus in GPX1 gene in the 13 patients with
ccRCC. The cancer-associated allele with five Ala repe-
ats was found in 61.5 % samples of renal cancer. Alle-
les 6 and 7 constituted a proportion of 27 and 11.5 % res-
pectively. The results are presented in Fig. 3 and Table.
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Fig. 1. Relative expression of GPX1 (n = 12) in ccRCC: samples 1–6 –
1–2 stages; 7–12 – 3–4 stages
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Fig. 2. Relative expression of GPX3 (n = 12) in ccRCC: samples 1–6 –
1–2 stages; 7–12 – 3–4 stages
Glutathione peroxidase functions in the detoxifica-
tion of hydrogen peroxide, and it is one of the most im-
portant antioxidant enzymes in humans. Consequently,
glutathione peroxidases might have dual role in the re-
gulation of hydroperoxide levels. GPXs are down-regu-
lated in different tumors, such as breast, gastric, and co-
lorectal cancers [13, 14], prostate cancer [15], thyroid
cancer of different origin [16, 17], and endometrial car-
cinoma [18]. SinceGPX3was always highly expres sed
in the corresponding healthy tissues, it has been sugges-
ted to exhibit tumor suppressor activity. Its main role
would be a prevention of cancer initiation, caused by
ROS-mediated DNA damage. Glutathione peroxidases
play a critical role in detoxifying reactive oxidative spe-
cies and maintaining the genetic integrity of mamma-
lian cells. Cancer ñells produce high amounts of reactive
oxygen species (ROS) and evade apoptosis. Hydrope-
roxides support proliferation, invasion, migration and
angiogenesis, but at higher levels they can induce apo-
ptosis, thus being pro- and anti-carcinogenic at the sa-
me time. Metastasizing and also apoptosis are inhibited
by all GPXs. GPXs that mediated through regulation of
other protein activities, may be important for early
stages of inflammation-mediated carcinogenesis [19].
A transcription of GPX1 is also regulated by oxygen
tension. Specifically, the humanGPX1 gene has two oxy-
gen response elements (OREs), which under normoxic
conditions are important for transcription [20]. Further,
it has been proposed that hypoxia-induced suppression
of GPX1 transcription may contribute to reperfusion in-
jury after low oxygen tension in cardiomyocytes [21].
Interestingly, hyperoxia enhances GPX1 transcription
in human umbilicalvein endothelial cells through a me-
chanism independent of the ORE [22], suggesting that
GPX1 transcription may be regulated in response to
oxygen tension by more than one mechanism.
Analysis of the novelGPX3 promoter identified the
Sp-1- and hypoxia-inducible factor-1A (HIF1A) bin-
ding sites, as well as the redox-sensitive metal response
element and antioxidant response element. HIF1A, acti-
vated by hypoxia, was identified as a strong trans-
criptional regulator of GPX3 expression, leading to al-
most 3-fold increase in the expression levels after 24 h
of hypoxia compared with normoxic conditions [23].
It was reported that promoter methylation of GPXs
family genes, namely GPX4 and GPX2, was the main
mechanism of expression loss in breast cancer [24]. In
our research, the methylation of promoter region was
not found. Therefore, the decline of expression, pro-
bably, could be conditioned by protein interactions. It
is known that the oxygen response element sequences
bind a nuclear complex that includes the nuclear factor,
Ku [25]. So, GPXs expression is very sensible to the
amount of oxygen in a ñell. As the innidiation and hy-
poxic effects in the ñell are closely bound, the expres-
sion level of GPX1 and GPX3 allows a judgement about
a possible innidiation. As was shown before,GPX1 gene
is characterized by polyalanine sequence polymor-
phism in the N-terminal region, which includes three
alleles with five, six or seven alanine (Ala) repeats. As
was reported in [26], this locus is polymorphic and the
allele with five Ala repeats is associated with breast
cancer risk. The results of our research confirmed predo-
minance of cancer-associated allele in ccRCC samples.
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Nucleotide number of PCR product
A
B
C
Fig. 3. Example of denaturing PAAG electrophoresis for GPX1 trinuc-
leotide polymorphic locus in renal clear cell carcinoma: A – Ala5 (ho-
mozygote); B – Ala6/Ala7; C – Ala5/Ala6 (heterozygotes)
GPX1 (N of Ala repeats) Renal cancer (n = 13)
5/5 4
6/6 1
7/7 –
Homozygosity 38.5 %
5/6 5
5/7 3
6/7 –
Heterozygosity 61.5 %
Genotype analysis of the human GPX-1 polyalanine polymorphism
in ccRCC samples
Conclusions. The results of our study confirm the
data of microarray and SAGE analysis for theGPX1 and
GPX3 genes. In the present work we have shown the es-
sential decrease in the relative expression level of GPX1
and GPX3 in ccRCC.
Establishment of possible genetic and epigenetic
mechanisms that contribute to the expression decline
has shown that promoter methylation was not a key me-
chanism. It was shown that the rarest allele trinucleo-
tide polymorphism was the allele with 7 Ala repeats for
the GPX1. The identification of differentially expres-
sed genes in clear-cell renal cell carcinoma would lead
to the identification of potential markers that will be of
significant value for diagnosis, prognosis, and treatment.
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Î. Î. Áîãàòèðüîâà, Ñ. Î. Âîç³àíîâ, Þ. Ì. Çãîííèê, Â. ². Êàøóáà
Ãåíåòè÷í³ òà åï³ãåíåòè÷í³ çì³íè â åêñïðåñ³¿ ãåí³â GPX1 ³ GPX3 çà
ñâ³òëîêë³òèííî¿ êàðöèíîìè íèðêè ëþäèíè
Ðåçþìå
Ìåòà. Çíàéòè ìîæëèâ³ ä³àãíîñòè÷í³ ³ ïðîãíîñòè÷í³ ìàðêåðè êàí-
öåðîãåíåçó.Ìåòîäè. Àíàë³ç äàíèõ SAGE ³ ì³êðî÷³ï³â, ê³ëüê³ñíà ÏËÐ
(Q-PCR), á³ñóëüô³òíå ñåêâåíóâàííÿ, ìåòèëñïåöèô³÷íà ÏËÐ. Ðåçóëü-
òàòè. Á³î³íôîðìàòè÷íèì àíàë³çîì áàç äàíèõ SAGE ³ ì³êðî÷³ï³â
âèÿâëåíî, ùî ãåíè, ÿê³ êîäóþòü ãëóòàò³îíïåðîêñèäàçó 1 ³ 3 (GPX1 ³
GPX3), ìàþòü íèçüêèé ð³âåíü åêñïðåñ³¿ ó òêàíèíàõ ðàêó íèðîê.
Äàí³ Q-PCRùîäî â³äíîñíî¿ åêñïðåñ³¿ ãåí³â GPX1 ³ GPX3 ï³äòâåðäè-
ëè, ùî çàçíà÷åí³ ãåíè ÷àñòî ³íàêòèâîâàí³ ó ñâ³òëîêë³òèíí³é êàðöè-
íîì³ íèðêè (ccRCC). Êîðåëÿö³¿ ì³æ ð³âíåì åêñïðåñ³¿ ³ ìåòèëþ-
âàííÿì ïðîìîòoðó ó æîäíîìó ðàç³ íå çíàéäåíî. Ïðîòå âñòàíîâëå-
íî, ùî àëåëü ç ï’ÿòüìà ALA-ïîâòîðàìè â N-ê³íöåâ³é ä³ëÿíö³ GPX1
º íàé÷àñò³øå ïîâòîðþâàíèì ïîë³ìîðôíèì âàð³àíòîì ó ïà-
ö³ºíò³â ç ccRCC. Âèñíîâêè. Íàø³ äàí³ ï³äòâåðäæóþòü ã³ïîòåçó,
ùî ãåíè GPX1 ³ GPX3 çàëó÷åí³ äî ïðîöåñó êàíöåðîãåíåçó ccRCC ³
ìîæóòü áóòè êàíäèäàòàìè íà ðîëü ãåí³â – ñóïðåñîð³â ïóõëèí
(TSGs, tumor suppressor genes) ïðè ðàêó íèðîê.
Êëþ÷îâ³ ñëîâà: êàðöèíîìà íèðêè, ãåíåòè÷íà òà åï³ãåíåòè÷íà
ðåãóëÿö³ÿ, õðîìîñîìà 3, ê³ëüê³ñíà ÏËÐ ó ðåàëüíîìó ÷àñ³, ð³âåíü ìå-
òèëþâàííÿ.
Å. Å. Ðóäåíêî, À. Â. Ãåðàùåíêî, Þ. Â. Ëàïñêàÿ, Î. À. Áîãàòûðåâà,
Ñ. À. Âîçèàíîâ, Þ. Ì. Çãîííèê, Â. È. Êàøóáà
Ãåíåòè÷åñêèå è ýïèãåíåòè÷åñêèå èçìåíåíèÿ â ýêñïðåññèè ãåíîâ
GPX1 è GPX3 ïðè ñâåòëîêëåòî÷íîé êàðöèíîìå ïî÷êè ÷åëîâåêà
Ðåçþìå
Öåëü. Íàéòè ïðåäïîëàãàåìûå äèàãíîñòè÷åñêèå è ïðîãíîñòè÷åñ-
êèå ìàðêåðû êàíöåðîãåíåçà.Ìåòîäû. Àíàëèç äàííûõ SAGE è ìèê-
ðî÷èïîâ, êîëè÷åñòâåííàÿ ÏÖÐ (Q-PCR), áèñóëüôèòíîå ñåêâåíèðî-
âàíèå, ìåòèëñïåöèôè÷åñêàÿ ÏÖÐ. Ðåçóëüòàòû. Áèîèíôîðìàòè-
÷åñêèì àíàëèçîì áàç äàííûõ SAGE è ìèêðî÷èïîâ âûÿâëåíî, ÷òî ãå-
íû, êîäèðóþùèå ãëþòàòèîíïåðîêñèäàçó 1 è 3 (GPX1 è GPX3), èìå-
þò íèçêèé óðîâåíü ýêñïðåññèè â òêàíÿõ ðàêà ïî÷åê. Äàííûå Q-
PCR ïî îòíîñèòåëüíîé ýêñïðåññèè ãåíîâ GPX1 è GPX3 ïîäòâåð-
äèëè, ÷òî ýòè ãåíû ÷àñòî èíàêòèâèðîâàíû â ñâåòëîêëåòî÷íîé
êàðöèíîìå ïî÷êè (ccRCC). Êîððåëÿöèè ìåæäó óðîâíåì ýêñïðåññèè
è ìåòèëèðîâàíèåì ïðîìîòoðà íè â îäíîì ñëó÷àå íå íàéäåíî. Îä-
íàêî îáíàðóæåíî, ÷òî àëëåëü ñ ïÿòüþ ALA-ïîâòîðàìè â N-êîíöå-
âîì ó÷àñòêå GPX1 ÿâëÿåòñÿ íàèáîëåå ÷àñòî ïîâòîðÿåìûì ïîëè-
ìîðôíûì âàðèàíòîì ó ïàöèåíòîâ ñ ccRCC. Âûâîäû. Íàøè ðå-
çóëüòàòû ïîäòâåðæäàþò ãèïîòåçó, ÷òî ãåíû GPX1 è GPX3 âî-
âëå÷åíû â ïðîöåññ êàíöåðîãåíåçà ccRCC è ìîãóò áûòü êàíäèäà-
òàìè íà ðîëü ãåíîâ – ñóïðåññîðîâ îïóõîëåé (TSGs, tumor suppres-
sor genes) ïðè ðàêå ïî÷åê.
Êëþ÷åâûå ñëîâà: êàðöèíîìà ïî÷êè, ãåíåòè÷åñêàÿ è ýïèãåíåòè-
÷åñêàÿ ðåãóëÿöèÿ, õðîìîñîìà 3, êîëè÷åñòâåííàÿ ÏÖÐ â ðåàëüíîì
âðåìåíè, óðîâåíü ìåòèëèðîâàíèÿ.
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